by MM360 Staff | May 31, 2025 | Myeloma News
Source: Pharmacy Times articles Emerging therapies targeting apolipoprotein C-III (ApoC3) are demonstrating significant promise in lowering triglycerides and reducing cardiovascular risk for patients with severe hypertriglyceridemia and rare disorders, such as...
by MM360 Staff | May 31, 2025 | Myeloma News
Source: Pharmacy Times articles Post Content Read More
by MM360 Staff | May 30, 2025 | Myeloma News
Source: Pharmacy Times articles Building on positive low-density lipoprotein cholesterol (LDL-C)-lowering seen in patients with atherosclerotic cardiovascular disease, inclisiran was found to induce meaningful and sustained LDL-C reductions following recent acute...
by MM360 Staff | May 30, 2025 | Myeloma News
Source: Pharmacy Times articles Enhanced dermatologic management reduces skin rash and improves quality of life for patients with EGFR-mutant non-small cell lung cancer. Read More
by MM360 Staff | May 30, 2025 | Myeloma News
Source: Pharmacy Times articles A study of early-onset colorectal cancer found significant racial disparities, with younger patients more frequently diagnosed at advanced stages. Read More
by MM360 Staff | May 30, 2025 | Myeloma News
Source: Pharmacy Times articles The FDA grants fast track designation to TEV-53408, a promising treatment for celiac disease designed to address gluten intolerance and improve patient outcomes. Read More